Literature DB >> 10086335

Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.

R Plattner1, S Gupta, R Khosravi-Far, K Y Sato, M Perucho, C J Der, E J Stanbridge.   

Abstract

Although an important contribution of ERK and JNK mitogen-activated protein kinase (MAPK) activation in Ras transformation of rodent fibroblasts has been determined, their role in mediating oncogenic Ras transformation of human tumor cells remains to be established. We have utilized the human HT1080 fibrosarcoma and DLD-1 colon carcinoma cell lines, which contain endogenous mutated and oncogenic N- and K-ras alleles, respectively, to address this role. Study of these cells is advantageous over Ras-transformed rodent model cell systems for two key reasons. First, the ras mutations occurred naturally in the progression of the tumors from which the cell lines were derived, rather than due to overexpression of an exogenously introduced gene. Second, although these tumor cells possess defects in multiple genetic loci, it has been established that mutated Ras contributes significantly to the transformed phenotype of these cells. Clonal variant lines of HT1080 and DLD-1 have been isolated which have lost the oncogenic ras allele and exhibit a corresponding impairment in growth transformation in vitro and in vivo. We found that upregulation of Raf/MEK/ERK and JNK correlated with expression of oncogenic Ras in HT1080, but not DLD-1 cells. Furthermore, inhibition of ERK activation in parental HT1080 cells caused the same changes in cell morphology and actin stress fiber organization seen with loss of expression of activated N-Ras(61K). Thus, we suggest that constitutive activation of the Raf/MEK/ERK and JNK pathways is necessary for Ras-induced transformation of HT1080 but not DLD-1 cells. These results emphasize that cell type differences exist in the signaling pathways by which oncogenic Ras causes transformation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086335     DOI: 10.1038/sj.onc.1202482

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Dissection of Ras-dependent signaling pathways controlling aggressive tumor growth of human fibrosarcoma cells: evidence for a potential novel pathway.

Authors:  S Gupta; R Plattner; C J Der; E J Stanbridge
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Combination of endostatin and a protein kinase Calpha DNA enzyme improves the survival of rats with malignant glioma.

Authors:  Dag R Sorensen; Marianne Leirdal; Per Ole Iversen; Mouldy Sioud
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

3.  Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma.

Authors:  Tatsuaki Tagami; Takuya Suzuki; Kiyomi Hirose; Jose Mario Barichello; Naoshi Yamazaki; Tomohiro Asai; Naoto Oku; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Drug Deliv Transl Res       Date:  2011-08       Impact factor: 4.617

4.  Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.

Authors:  Yufang Wang; Sérgia Velho; Efsevia Vakiani; Shouyong Peng; Adam J Bass; Gerald C Chu; Jessica Gierut; James M Bugni; Channing J Der; Mark Philips; David B Solit; Kevin M Haigis
Journal:  Cancer Discov       Date:  2012-12-28       Impact factor: 39.397

5.  Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells.

Authors:  S Gupta; S Stuffrein; R Plattner; M Tencati; C Gray; Y E Whang; E J Stanbridge
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

Review 6.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

7.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Authors:  Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

8.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

Authors:  Juran Kato-Stankiewicz; Irina Hakimi; Gang Zhi; Jie Zhang; Ilya Serebriiskii; Lea Guo; Hironori Edamatsu; Hiroshi Koide; Sanjay Menon; Robert Eckl; Sukumar Sakamuri; Yingchun Lu; Quin-Zene Chen; Seema Agarwal; William R Baumbach; Erica A Golemis; Fuyuhiko Tamanoi; Vladimir Khazak
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

9.  Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations.

Authors:  Prashant Bavi; Sarita E Prabhakaran; Jehad Abubaker; Zeeshan Qadri; Thara George; Nasser Al-Sanea; Alaa Abduljabbar; Luai H Ashari; Samar Alhomoud; Fouad Al-Dayel; Azhar R Hussain; Shahab Uddin; Khawla S Al-Kuraya
Journal:  Mol Cancer       Date:  2010-07-30       Impact factor: 27.401

10.  Nuclear factor of activated T cells balances angiogenesis activation and inhibition.

Authors:  Tetiana A Zaichuk; Emelyn H Shroff; Rebekah Emmanuel; Stephanie Filleur; Thomas Nelius; Olga V Volpert
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.